Gabapentin and Pregabalin for the Treatment of Anxiety Disorders.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 228, doi. 10.1002/cpdd.446
- By:
- Publication type:
- Article
Works matching IS 2160763X AND DT 2018 AND VI 7 AND IP 3
Results: 14
1
2
2017 CPDD Peer Reviewers.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 347, doi. 10.1002/cpdd.443
- Publication type:
- Article
3
Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 298, doi. 10.1002/cpdd.428
- By:
- Publication type:
- Article
4
Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 233, doi. 10.1002/cpdd.422
- By:
- Publication type:
- Article
5
In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF‐00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 244, doi. 10.1002/cpdd.411
- By:
- Publication type:
- Article
6
Evaluation of Bioequivalence Between 0.5‐mg Dutasteride Capsules Manufactured by GlaxoSmithKline and an Existing Formulation: A Randomized Study in Healthy Japanese Male Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 341, doi. 10.1002/cpdd.407
- By:
- Publication type:
- Article
7
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 223, doi. 10.1002/cpdd.400
- Publication type:
- Article
8
The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 277, doi. 10.1002/cpdd.397
- By:
- Publication type:
- Article
9
Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 332, doi. 10.1002/cpdd.393
- By:
- Publication type:
- Article
10
Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 263, doi. 10.1002/cpdd.383
- By:
- Publication type:
- Article
11
Population Pharmacokinetic Evaluation and Missed‐Dose Simulations for Eslicarbazepine Acetate Monotherapy in Patients With Partial‐Onset Seizures.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 287, doi. 10.1002/cpdd.382
- By:
- Publication type:
- Article
12
Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 319, doi. 10.1002/cpdd.381
- By:
- Publication type:
- Article
13
Pharmacokinetics and Bioequivalence of Branded and Generic Formulations of Dofetilide 0.5‐mg Capsules After Single‐Dose Administration in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 311, doi. 10.1002/cpdd.371
- By:
- Publication type:
- Article
14
Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High‐Performance Liquid Chromatography‐Mass Spectrometry Method.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 256, doi. 10.1002/cpdd.348
- By:
- Publication type:
- Article